Atopic dermatitis: SGAxBSA tool appears valid for clinical signs

  • J Am Acad Dermatol

  • Brian Richardson, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • A clinician-derived, 5-point global assessment and body surface area (SGAxBSA) tool appears valid and feasible for signs of atopic dermatitis (AD) in clinical practice.

Why this matters

  • Current instruments for signs of AD may not be suitable for clinical practice because of their complexity.

Key results

  • SGAxBSA score was significantly correlated with the Eczema Area and Severity Index (r=0.91), average daily pruritus (r=0.71), and patient global assessment (r=0.74).
  • SGAxBSA score also was correlated with a derived global scale comprising the average of 4 signs rated between 0 and 3 (r=0.77; P<.0001 for all>
  • Acceptability, responsiveness, and floor or ceiling effects of SGAxBSA were classified as adequate.
  • Severity banding was maximized at 1, 21, and 87 (κ=0.4902).

Study design

  • 138 patients with AD (325 total clinic visits) were included.
  • Funding: None.

Limitations

  • Retrospective.